Add to ORKGmonoclonal antibody bevacizumab (Avastin ®), which is the only anti-angiogenic agent approved for treatment of cancer. Copyright © 2005 S. Karger AG, Base
Tumor angiogenesis, which is necessary for breast cancer growth, invasion and metastases, is regulat...
Clinical trials with angiogenesis inhibitors Angiogenesis is essential for tumorgrowth and metastasi...
The approval in 2004 of bevacizumab (Avastin), a neutralizing monoclonal antibody directed against v...
Anti-angiogenic therapy is one of the promising strategies for many types of solid cancers. Bevacizu...
Anti-angiogenic therapy is one of the promising strategies for many types of solid cancers. Bevacizu...
International audienceWhen the VEGF-A-targeting monoclonal antibody bevacizumab (Avastin®) entered c...
Tumor angiogenesis is a key event that governs tumor progression and metastasis. It is controlled by...
It is well established that the angiogenic switch is a criti-cal step in carcinogenesis; clinical su...
Tumor angiogenesis defines tumor growth as it is dependent on generation of new blood vessels. Over ...
In the past decade, many angiogenesis inhibitors have been developed for clinical use in oncology. S...
Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen in vitro and an an...
Andrew Eichholz, Shairoz Merchant, Andrew M GayaDepartment of Clinical Oncology, Guy’s and...
Bevacizumab (Avastin®; Genentech, South San Francisco, CA) is a monoclonal antibody that targets the...
The vascular endothelial growth factor (VEGF) family of polypeptide growth factors regulates a famil...
The importance of angiogenesis in tumour growth and development is well known. Angiogenesis is impli...
Tumor angiogenesis, which is necessary for breast cancer growth, invasion and metastases, is regulat...
Clinical trials with angiogenesis inhibitors Angiogenesis is essential for tumorgrowth and metastasi...
The approval in 2004 of bevacizumab (Avastin), a neutralizing monoclonal antibody directed against v...
Anti-angiogenic therapy is one of the promising strategies for many types of solid cancers. Bevacizu...
Anti-angiogenic therapy is one of the promising strategies for many types of solid cancers. Bevacizu...
International audienceWhen the VEGF-A-targeting monoclonal antibody bevacizumab (Avastin®) entered c...
Tumor angiogenesis is a key event that governs tumor progression and metastasis. It is controlled by...
It is well established that the angiogenic switch is a criti-cal step in carcinogenesis; clinical su...
Tumor angiogenesis defines tumor growth as it is dependent on generation of new blood vessels. Over ...
In the past decade, many angiogenesis inhibitors have been developed for clinical use in oncology. S...
Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen in vitro and an an...
Andrew Eichholz, Shairoz Merchant, Andrew M GayaDepartment of Clinical Oncology, Guy’s and...
Bevacizumab (Avastin®; Genentech, South San Francisco, CA) is a monoclonal antibody that targets the...
The vascular endothelial growth factor (VEGF) family of polypeptide growth factors regulates a famil...
The importance of angiogenesis in tumour growth and development is well known. Angiogenesis is impli...
Tumor angiogenesis, which is necessary for breast cancer growth, invasion and metastases, is regulat...
Clinical trials with angiogenesis inhibitors Angiogenesis is essential for tumorgrowth and metastasi...
The approval in 2004 of bevacizumab (Avastin), a neutralizing monoclonal antibody directed against v...